(VIANEWS) – The NASDAQ ended the session with BeiGene (BGNE) rising 5.1% to $138.52 on Tuesday while NASDAQ jumped 0.25% to $10,829.50.

About BeiGene

BeiGene, Ltd. is a biotechnology firm that focuses on the discovery, development, manufacture, and marketing of various medicines around the world. BRUKINSA is used to treat relapsed/refractory (R/R), mantle lymphoma (R/R); Tislelizumab for R/R classic Hodgkin’s lymphoma. REVLIMID can treat multiple myeloma. KYPROLIS can treat R/R multiple lymphoma. SYLVANT treats idiopathic multiplecentric castleman disorder. QARZIBA will treat R/R neuroblastomarib to treat various solid cancer. Its clinical stage candidates include Zanubrutinib (a BTK inhibitor for lymphomas); Tislelizumab (an anti-PD-1 antibody that treats solid and hematological carcinomas); KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; Pamiparib to treat various solid tumors; and Sitravatinib to treat NSCLC and melanoma. BGB -A333 is a PD-1 inhibitor that can be used to treat different solid tumors. Ociperlimab is a TIGIT inhibit to treat multiple solid cancers. BGB -11417 is a small molecule Bcl-2 antagonist to treat advanced B-cell malignancies. BGB -A445, which treats OX40 agonist antibodies, Zanidatamab to treat breast, gastric, and other types of cancer. BGB -A425, containing-3, containing-3, a T-cell-cell immunoglobulin-domain containing-3-domain containing-3-domain containing-3-domain containing-3-domain containing-3-domain containing-3-domain containing-domain containing-3-domain containing-3-domain containing-3-domain containing-3-domain containing-3-domain containing-1 inhibitor, and HPK1; and BGB1502525, a small molecule to blocker Strategic collaborations have been established with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb and Novartis AG. BeiGene, Ltd., was founded in 2010, and has its headquarters in Cambridge, Massachusetts.

Earnings Per Share

As for profitability, BeiGene has a trailing twelve months EPS of $-19.13.

Return on Equity (TTM)

BeiGene’s ROE is -38.71%.


Today’s last reported volume for BeiGene is 240270, 3.1% above its average volume of 233033.

BeiGene’s last close was $131.80, 66.4% below its 52-week high of $392.30.

BeiGene’s Sales

BeiGene’s sales growth is 112% for the ongoing quarter and 93.1% for the next. The company’s growth estimates for the ongoing quarter and the next is 24.1% and 22.2%, respectively.

BeiGene’s Revenue

Year-on-year quarterly revenue growth declined by 49.4%, now sitting on 877.04M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

BeiGene’s stock is considered to be overbought (>=80).

BeiGene’s Stock Yearly Top and Bottom Value

BeiGene’s stock is valued at $138.52 at 18:19 EST, way below its 52-week high of $392.30 and way higher than its 52-week low of $118.18.

BeiGene’s Moving Average

BeiGene’s worth is way under its 50-day moving average of $173.66 and way below its 200-day moving average of $189.41.

More news about BeiGene (BGNE).


Please enter your comment!
Please enter your name here